[Hormone-refractory prostate cancer].
Hormone-refractory prostate cancer is an advanced stage of the metastatic disease; it has a poor prognosis and a short median survival, about 9 to 18 months. The current article is based on a literature review regarding the prognostic factors and medical treatments, with a focus on recent advances in chemotherapy. With the use of docetaxel that increases the median survival of this disease and improves the symptoms, new clinical protocols have been developed, with promising results; these protocols propose a combination with calcitriol or antiangiogenic agents. Supportive care is also an important part of the treatment due to the high level of bone involvement and its consequences. Such recent advances constitute a real progress in the management of prostate cancer, namely the pharmacological combinations with a promising efficacy and little toxicity.
Alexandre
I
I
Service d'oncologie médicale, groupe hospitalier Pitié-Salpêtrière, Assistance Publique, Hôpitaux de Paris, 41-87, boulevard de l'Hôpital, 75013 Paris, France.
Rixe
O
O
D000328:Adult; D000368:Aged; D000726:Androgen Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D002117:Calcitriol / Q000008:administration & dosage / Q000627:therapeutic use; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D003131:Combined Modality Therapy; D004164:Diphosphonates / Q000627:therapeutic use; D000077143:Docetaxel; D006801:Humans; D008297:Male; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy / Q000401:mortality; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D043823:Taxoids / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors; D014815:Vitamins / Q000008:administration & dosage / Q000627:therapeutic use
D000726:Androgen Antagonists; D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D043823:Taxoids; D014815:Vitamins; D000077143:Docetaxel; D002117:Calcitriol